These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

192 related articles for article (PubMed ID: 15142508)

  • 1. [Meta-analysis on safety and efficacy of liposomal amphotericin B in the empirical treatment of febrile neutropenia].
    Badia X; Roset M; Carreras E; Ausin I; Herrera L
    Med Clin (Barc); 2004 May; 122(16):610-6. PubMed ID: 15142508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections.
    Moen MD; Lyseng-Williamson KA; Scott LJ
    Drugs; 2009; 69(3):361-92. PubMed ID: 19275278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever.
    Walsh TJ; Pappas P; Winston DJ; Lazarus HM; Petersen F; Raffalli J; Yanovich S; Stiff P; Greenberg R; Donowitz G; Schuster M; Reboli A; Wingard J; Arndt C; Reinhardt J; Hadley S; Finberg R; Laverdière M; Perfect J; Garber G; Fioritoni G; Anaissie E; Lee J;
    N Engl J Med; 2002 Jan; 346(4):225-34. PubMed ID: 11807146
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
    Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
    N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Voriconazole versus amphotericin B in cancer patients with neutropenia.
    Jørgensen KJ; Gøtzsche PC; Johansen HK
    Cochrane Database Syst Rev; 2006 Jan; (1):CD004707. PubMed ID: 16437492
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia.
    Jørgensen KJ; Gøtzsche PC; Dalbøge CS; Johansen HK
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD004707. PubMed ID: 24563222
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An open study of the comparative efficacy and safety of caspofungin and liposomal amphotericin B in treating invasive fungal infections or febrile neutropenia in patients with haematological malignancy.
    Ellis M; Frampton C; Joseph J; Alizadeh H; Kristensen J; Hauggaard A; Shammas F
    J Med Microbiol; 2006 Oct; 55(Pt 10):1357-1365. PubMed ID: 17005784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomized comparative trial evaluating the safety and efficacy of liposomal amphotericin B (Fungisome) versus conventional amphotericin B in the empirical treatment of febrile neutropenia in India.
    Jadhav MP; Shinde VM; Chandrakala S; Jijina F; Menon H; Arora B; Kurkure PA; Parikh PM; Kshirsagar NA
    Indian J Cancer; 2012; 49(1):107-13. PubMed ID: 22842177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients.
    Cagnoni PJ
    J Antimicrob Chemother; 2002 Feb; 49 Suppl 1():81-6. PubMed ID: 11801587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacoeconomic analysis of liposomal amphotericin B versus voriconazole for empirical treatment of febrile neutropenia.
    Collins CD; Stuntebeck ER; DePestel DD; Stevenson JG
    Clin Drug Investig; 2007; 27(4):233-41. PubMed ID: 17358095
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections.
    Blyth CC; Hale K; Palasanthiran P; O'Brien T; Bennett MH
    Cochrane Database Syst Rev; 2010 Feb; 2010(2):CD006343. PubMed ID: 20166083
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia.
    Walsh TJ; Teppler H; Donowitz GR; Maertens JA; Baden LR; Dmoszynska A; Cornely OA; Bourque MR; Lupinacci RJ; Sable CA; dePauw BE
    N Engl J Med; 2004 Sep; 351(14):1391-402. PubMed ID: 15459300
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Meta-analysis on safety and efficacy of liposomal amphotericin B in the empirical treatment of febrile neutropenia].
    Grau S; Marín M; Mateu-de Antonio J
    Med Clin (Barc); 2005 Jan; 124(1):38-9; author reply 39. PubMed ID: 15683629
    [No Abstract]   [Full Text] [Related]  

  • 14. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
    Johnson JR
    N Engl J Med; 2002 May; 346(22):1745-7; author reply 1745-7. PubMed ID: 12037157
    [No Abstract]   [Full Text] [Related]  

  • 15. [Voriconazol and liposomal amphotericin B: true evidence of their differences with regard to effectiveness and safety].
    Soto J
    Med Clin (Barc); 2005 Jan; 124(1):37-8. PubMed ID: 15683627
    [No Abstract]   [Full Text] [Related]  

  • 16. Voriconazole versus liposomal amphotericin B for empirical antifungal therapy.
    Ullmann AJ; Heussel CP; Cornely OA
    N Engl J Med; 2002 May; 346(22):1745-7; author reply 1745-7. PubMed ID: 12041526
    [No Abstract]   [Full Text] [Related]  

  • 17. Institutional experience with voriconazole compared with liposomal amphotericin B as empiric therapy for febrile neutropenia.
    Shehab N; DePestel DD; Mackler ER; Collins CD; Welch K; Erba HP
    Pharmacotherapy; 2007 Jul; 27(7):970-9. PubMed ID: 17594202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy for febrile neutropenia in Australia.
    Al-Badriyeh D; Liew D; Stewart K; Kong DC
    J Antimicrob Chemother; 2009 Jan; 63(1):197-208. PubMed ID: 19001450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Amphotericin B and its new formulations: pharmacologic characteristics, clinical efficacy, and tolerability.
    Tiphine M; Letscher-Bru V; Herbrecht R
    Transpl Infect Dis; 1999 Dec; 1(4):273-83. PubMed ID: 11428998
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The lipid formulations of amphotericin B.
    Herbrecht R; Natarajan-Amé S; Nivoix Y; Letscher-Bru V
    Expert Opin Pharmacother; 2003 Aug; 4(8):1277-87. PubMed ID: 12877636
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.